Phase 12a Study Assessing Safety and Activity of CCS1477 Alone and With Other Drugs in Adults With Advanced Blood Cancers

What this Trial Is About

Researchers are studying CCS1477 inobrodib to evaluate its safety, tolerability, pharmacokinetics, and biological activity in adults with advanced blood cancers, including Non-Hodgkin Lymphoma, Multiple Myeloma, Acute Myeloid Leukemia, Peripheral T-cell lymphoma, and High Risk Myelodysplastic Syndrome. This Phase 12a interventional trial aims to understand how CCS1477 works alone and in combination with other drugs in these conditions. Participants receive CCS1477 as an oral capsule, either alone or combined with other medications such as lenalidomide, pomalidomide-dexamethasone, bortezomib-dexamethasone, ixazomib-dexamethasone, elranatamab, teclistamab, daratumumab, azacitidine, and venetoclax. Treatment involves dose escalation and expansion phases with various combinations tailored to specific types of blood cancers. The study is non-randomized and sequential, with participants assigned to different arms based on their disease and treatment combinations. Throughout the study, participants undergo regular assessments to monitor safety, including tracking treatment-related adverse events and laboratory abnormalities for up to 12 months. Researchers also measure response rates, duration of response, and pharmacokinetic parameters such as drug exposure over 35 days. The study involves ongoing monitoring during and after treatment to evaluate the effects of CCS1477 and its combinations in these hematological malignancies.

Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies